Title: Early Phase Modelling – Estimating the Costs and Effectiveness of a Pharmaceutical before Clinical Trial
Date: Wednesday, February 20, 2019
Time: 04:00 PM Central European Time
Duration: 1 hour
Approaching market launch, new pharmaceutical products need to be included in national reimbursement schemes. Key success factors for reimbursement rely on preparations performed early in the product development program, where product-specific identification of opportunities and challenges associated with the reimbursement process are important. This allows for plans to be drawn-up and activities to be initiated in a timely manner.
This webinar offers an overview of the benefits early-phase, health-economic modelling can provide, at a stage when the outcome of the product development program is still largely unknown. Early-Phase Modelling balances between accuracy and manageability, and represents an easy to grasp, conceptual overview of your product and its potentials regarding reimbursement.
Senior Manager, Health Economics & Outcomes Research
Åse Björstad is a licensed pharmacist, and holds a PhD in Medicine with special emphasis on leukocyte biology from the University of Gothenburg, Sweden. Following her doctoral thesis, she held a position as a lecturer at the faculty of Pharmacy and Pharmaceutical Sciences at the University of Umeå. In 2010, she was recruited to Nordic Health Economics (now PharmaLex) and has since then gained 9 years of experience from hands-on work and project management within health economics and real-world evidence studies.
As a health economist, Åse has been engaged in a wide range of projects, including Early Phase Modelling to inform clients on what is needed for a successful reimbursement process for their product. The projects have concerned a variety of disease areas, for example; allergic diseases, oncology, cardiovascular diseases, ophthalmology, endocrinology, neurology, rheumatology, surgical interventions and various orphan and ultra-orphan diseases.
With her multi-disciplinary background, Åse is highly valued among clients for her ability to provide timely advice on health economic opportunities of emerging healthcare interventions, and on how Early Phase Modelling could be used as a tool for these purposes.